Literature DB >> 14684414

Mature dendritic cells can enhance CD8+ cell noncytotoxic anti-HIV responses: the role of IL-15.

JoAnn Castelli1, Elaine K Thomas, Michel Gilliet, Yong-Jun Liu, Jay A Levy.   

Abstract

The CD8+ cell noncytotoxic anti-HIV response (CNAR) is associated with a long-term healthy clinical state in HIV-infected individuals. Over time CNAR is reduced concomitant with progression to disease. In studies to evaluate whether the interaction between CD8+ cells and dendritic cells (DCs) could increase CNAR, CD8+ cells from individuals who showed a decrease in this antiviral activity were cocultured with monocyte-derived dendritic cells matured with CD40 ligand. After coculture with these mature DCs, the CD8+ cells showed an increase in CNAR greater than that observed with CD8+ cells costimulated with CD3/CD28 antibodies. This antiviral response appeared to be mediated primarily by production of interleukin-15 (IL-15) by the mature DCs. Purified IL-15 also enhanced CNAR, whereas IL-12 showed no substantial effect. These studies provide another potential approach by which the immune system in HIV infection could be restored by cytokine therapy, particularly IL-15 administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684414     DOI: 10.1182/blood-2003-06-1913

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Interleukin-15 enhances T-cell responses by stimulation with dendritic cells.

Authors:  Yu Zhao; Ke Cheng; Yang Wu; Xing-Chen Peng; Ye Chen; Ben-Xu Tan; Jun Ge; Hang Dong; Meng Wei; Feng Gao; Jing-Mei Su; Jian-Mei Hou; Ji-Yan Liu
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

Review 3.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

4.  Analysis of the CD8+ T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.

Authors:  M Scott Killian; Fernando Teque; Ramu Sudhagoni
Journal:  Immunogenetics       Date:  2017-07-22       Impact factor: 2.846

5.  Association of IL-12+ DC with High CD3+CD4-DR+ lymphocyte counts in long-term HIV-infected hemophilia patients with clinically stable disease.

Authors:  Volker Daniel; Cord Naujokat; Mahmoud Sadeghi; Rainer Zimmermann; Angela Huth-Kühne; Gerhard Opelz
Journal:  J Clin Immunol       Date:  2007-09-19       Impact factor: 8.317

6.  CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy.

Authors:  M Scott Killian; Jeremy Roop; Sharon Ng; Frederick M Hecht; Jay A Levy
Journal:  J Clin Immunol       Date:  2009-02-03       Impact factor: 8.317

7.  Immunophenotypic alterations in acute and early HIV infection.

Authors:  Lena Al-Harthi; Sam MaWhinney; Elizabeth Connick; Robert T Schooley; Jeri E Forster; Constance Benson; Melanie Thompson; Franklyn Judson; Frank Palella; Alan Landay
Journal:  Clin Immunol       Date:  2007-10-03       Impact factor: 3.969

8.  The CD8 antiviral factor (CAF) can suppress HIV-1 transcription from the long terminal repeat (LTR) promoter in the absence of elements upstream of the CATATAA box.

Authors:  Varsha Shridhar; Yue Chen; Phalguni Gupta
Journal:  Virol J       Date:  2014-07-21       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.